Outgoing PhRMA chief cautions industry not to backslide
This article was originally published in Scrip
Executive Summary
Billy Tauzin, in his final address to the Pharmaceutical Research & Manufacturers of America (PhRMA) before leaving his post as the group's president, emphasised the changes he had spearheaded at the organisation in his five-year tenure – and at its annual meeting on 18 March strongly urged that the member companies not let PhRMA slip back to the policies it pursued before he took the helm.